Proprietary delivery platform addresses a longstanding challenge in oncology

• Proprietary nanoparticle platform is designed to deliver RNA therapeutics directly to tumors beyond the liver, addressing one of the key historical challenges with RNA-based medicines.
• Phase 0 clinical trial demonstrated successful accumulation of TTX-MC138 in metastatic lesions in a human patient, providing early clinical validation of the Company's targeted delivery technology.
• Versatile platform supports multiple payloads—including RNA therapeutics, peptides, proteins, radionuclides, and antibodies—and offers long-term partnering opportunities beyond TransCode's internal pipeline.

Lead candidate targets metastatic disease with encouraging early results

• TTX-MC138 is a first-in-class RNA therapeutic candidate targeting microRNA-10b, a master regulator of cancer invasion and metastasis.
• Completed Phase 1a trial met its primary endpoint of safety and tolerability with no dose-limiting toxicities across all dose levels, while 64% (9 out of 14) of evaluable patients achieved stable disease and three patients remain on therapy.
• Phase 2a trial launched in ctDNA-positive colorectal cancer patients with minimal residual disease, a setting with significant unmet need and the potential to intervene before metastatic recurrence.

Diversified oncology pipeline provides multiple avenues for value creation

• Company has evolved into a three-platform oncology business spanning RNA therapeutics, cancer vaccines, and immuno-oncology following the acquisition of Polynoma and the licensing of Unleash Immuno Oncolytics’ pipeline.
• Seviprotimut-L is a Phase 3 melanoma vaccine candidate with FDA Fast Track and Orphan Drug designations that demonstrated encouraging efficacy trends in selected patient populations.
• Additional preclinical programs, including UIO-524, TTX-siPD-L1, and TTX-RIGA, expand the pipeline across multiple high-value oncology indications while leveraging the Company's proprietary delivery technology.

Multiple near-term clinical catalysts could drive shareholder value

• Phase 2a enrollment initiation and enrollment updates for TTX-MC138 expected throughout 2026.
• Preliminary Phase 2a clinical data anticipated beginning in late 2026, followed by the Phase 1a final readout and additional Phase 2a readouts during 2027.
• Advancement of additional pipeline assets toward IND-enabling studies provides additional news flow beyond the lead program as funding allows.

World-class scientific foundation with expanding strategic validation

• Founding technology was developed by Harvard Medical School/Massachusetts General Hospital researchers focused on overcoming RNA delivery challenges.
• Scientific Advisory Board includes internationally recognized leaders in RNA therapeutics, oncology, and drug development, including pioneers from institutions such as Massachusetts General Hospital and Alnylam.
• Collaboration with Quantum Leap Health Care Collaborative provides access to an established national oncology clinical trial network, supporting efficient patient enrollment and trial execution.

Compelling risk/reward supported by capital investment and partnership potential

• Approximately $100 million has been invested in the Company since its IPO through financings and non-dilutive grants, supporting advancement of multiple oncology programs.
• Management is actively pursuing strategic partnerships across both therapeutic programs and the proprietary delivery platform, creating potential non-dilutive value creation opportunities.
• Current valuation represents a fraction of the estimated capital required to build a comparable multi-platform oncology pipeline, providing substantial leverage to successful clinical execution.